Android app on Google Play

Canaccord Genuity on Life Sciences/Specialty Pharma: Top Summer Catalyst-Driven Ideas To Trump 'Macro' Influence

June 21, 2012 10:53 AM EDT Send to a Friend
Get Alerts TEVA Hot Sheet
Price: $54.42 +0.18%

Rating Summary:
    14 Buy, 16 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 21 | Down: 35 | New: 7
Trade TEVA Now!
Join SI Premium – FREE
Canaccord Genuity on Life Sciences/Specialty Pharma: Top Summer Catalyst-Driven Ideas To Trump 'Macro' Influence

Analyst, Randall Stanicky, said, "Broader market sentiment is clearly challenging, which was apparent in investor meetings we held in four different cities over the last week. We expect uncertainty linked to a host of issues including health reform (within the next week), macro/EU challenges (unlikely to fade), summer lull and November election to continue to impact volumes and stocks. That said, we do see opportunity for single-stock performance in catalyst-driven names where events will outweigh macro over the next three months. There are several stocks with major events but our top two catalyst-driven names are Teva Pharma (Nasdaq: TEVA) and Impax (Nasdaq: IPXL) (both BUY). BUY-rated Warner Chilcott (Nasdaq: WCRX) brings potential for upside given its ongoing review of strategic alternatives on admittedly low visibility but with little priced in given the recent pull-back."

TEVA (BUY, $52 PT) - Copaxone trial decision imminent and the most important catalyst

IPXL (BUY, $29 PT) – Top small cap idea with three catalysts set to come near-term




You May Also Be Interested In


Related Categories

Analyst Comments, Trader Talk

Related Entities

Canaccord Genuity

Add Your Comment